A Phase II, Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 microg Administered Once Daily (in the Evening) and Tiotropium 2.5 microg Administered Twice Daily Delivered by the Respimat Inhaler for Four Weeks Versus Placebo in Patients With Moderate Persistent Asthma.

Trial Profile

A Phase II, Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 microg Administered Once Daily (in the Evening) and Tiotropium 2.5 microg Administered Twice Daily Delivered by the Respimat Inhaler for Four Weeks Versus Placebo in Patients With Moderate Persistent Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 23 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Planned End Date changed from 1 Jun 2011 to 1 Aug 2011, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top